Skip to main content Help with accessibility Skip to main navigation



Treating chronic obstructive pulmonary disease (NICE TA461)
NICE TA461 - Roflumilast for treating chronic obstructive pulmonary disease


Amber level 0



Nice TA:


Commissioning responsibility:


PbR excluded:


BNF chapter:
Respiratory system


Roflumilast, as an add-on to bronchodilator therapy, is recommended as an option for treating severe chronic obstructive pulmonary disease in adults with chronic bronchitis, only if:
•the disease is severe, defined as a forced expiratory volume in 1 second (FEV1) after a bronchodilator of less than 50% of predicted normal, and
•the person has had 2 or more exacerbations in the previous 12 months despite triple inhaled therapy with a long-acting muscarinic antagonist, a long-acting beta-2 agonist and an inhaled corticosteroid.
Treatment with roflumilast should be started by a specialist in respiratory medicine.


LSCMMG Recommendation:

Amber level 0

Reason for decision:

Suitable for GP prescribing following recommendation/initiation by specialist

Supporting documents:

Decisions of Lancashire local decision making groups

Amber 0
Amber 0
Amber 0
Amber 0
Amber 0
Amber 0
Amber 0
Amber 0
What do the colours mean?

Last Updated: 01 - Sep - 2017